Target
- Clinical Development
- Regulatory Affairs
- Medical Affairs
The problem
Aligning Clinical Development, Regulatory Affairs, and Medical Affairs teams on shared evidence takes 3 to 6 months, time the protocol timeline can't afford. The result: delayed regulatory strategy and costly late-stage pivots.
The solution
Comprehensive clinical landscape and endpoint analysis across 5 target conditions, delivered in under one month, covering clinical studies, meta-analyses, and systematic reviews.
100% sourced and traceable evidence base, with quality control metrics documenting model performance provided alongside all findings
AI-powered extraction and normalization of endpoint strategies across heterogeneous trial protocols, with standardized classification of intervention types and sponsor maturity profiles.
Dual-format deliverables (analytical report + structured dataset) enabling immediate cross-functional use across Medical Affairs, Clinical Development, and Regulatory teams.
The impact
AstraZeneca's Vaccines and Antibody Therapies division validated a new approach to protocol design across 5 disease areas in under a month, compressing a timeline that would typically require 3 to 6 months internally. The fully sourced evidence base aligned cross-functional teams, eliminated evidence inconsistencies, and delivered more robust scientific rationale for each clinical protocol.
0% hallucination rate validated by the AstraZeneca team.
“ArcaScience delivered a comprehensive clinical landscape and endpoints analysis across five target conditions in under a month. The 100% sourced dataset and structured BRA framework gave our team the confidence to validate our regulatory strategy with credible, actionable evidence.”